Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Escherichia sp., Klebsiella sp.

ABSTRACT: Multi-site Gram-negative Surveillance Initiative MuGSI ESBL panel

PROVIDER: PRJNA835887 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19200964_1.fastq.gz	Fastqsanger.gz
	SRR19200964_2.fastq.gz	Fastqsanger.gz
	SRR19200965_1.fastq.gz	Fastqsanger.gz
	SRR19200965_2.fastq.gz	Fastqsanger.gz
	SRR19200966_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 58

Similar Datasets

RNAseq transcriptome analysis of K. pneumoniae MS6671 with PBT2 and colistin

Project description:The emergence of polymyxin resistance in carbapenem-resistant and extended-spectrum -lactamase (ESBL)-producing bacteria is a critical threat to human health, and new treatment strategies are urgently required. Here, we investigated the ability of the safe-for-human use ionophore PBT2 to restore antibiotic sensitivity in polymyxin-resistant, ESBL-producing, carbapenem-resistant Gram-negative human pathogens. PBT2 was observed to resensitize Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii and Pseudomonas aeruginosa to last-resort polymyxin class antibiotics, including the less-toxic next-generation polymyxin derivative, FADDI-287. We were unable to select for mutants resistant to PBT2 + FADDI-287 in polymyxin resistant E. coli containing a plasmid-borne mcr-1 gene or K. pneumoniae carrying a chromosomal mgrB mutation. Using a highly invasive K. pneumoniae strain engineered for polymyxin resistance through mgrB mutation, we successfully demonstrated the efficacy of PBT2 + FADDI-287 in vivo for the treatment of Gram-negative sepsis. These data present a new treatment modality to break antibiotic resistance in high priority polymyxin-resistant Gram-negative pathogens.

2020-07-01 | GSE153553 | GEO

Environmental Surveillance of ESBL and Carbapenemase-Producing Gram-Negative Bacteria from a Ghanaian Tertiary Hospital

Project description:Environmental Surveillance of ESBL and Carbapenemase-Producing Gram-Negative Bacteria in a hospital in Ghana

| PRJEB46496 | ENA

Project description:Environmental Surveillance of ESBL and Carbapenemase-Producing Gram-Negative Bacteria in a Ghanaian Tertiary Hospital

| PRJNA750808 | ENA

Klebsiella pneumoniae

Project description:Gram Negative Bacteria Genome sequencing and assembly

| PRJNA312481 | ENA

Homo sapiens

Project description:Multi-drug Resistant Gram-negative Bacteria - CCHE57357

| PRJNA603448 | ENA

Klebsiella pneumoniae, Acinetobacter sp., Pseudomonas aeruginosa

Project description:WGS of Carbapenem-resistant Gram-negative clinical isolates from Mali

| PRJNA513871 | ENA

RNAseq transcriptome analysis of K. pneumoniae MS6671 and E. coli MS8345 treated with PBT2

Project description:The emergence of colistin resistance in carbapenem-resistant and extended-spectrum ß-lactamase (ESBL)-producing bacteria is a significant threat to human health, and new treatment strategies are urgently required. Here we investigated the ability of the safe-for-human use ionophore PBT2 to restore antibiotic sensitivity in several polymyxin-resistant, ESBL-producing, carbapenem resistant Gram-negative human pathogens. PBT2 was observed to resensitize Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa to last-resort polymyxin class antibiotics, including a ‘next generation’ polymyxin derivative, FADDI-287. To gain additional insight into the potential mechanism of action of PBT2, we analyzed the transcriptome of K. pneumoniae and E. coli in the presence of sub-inhibitory concentrations of PBT2. Treatment with PBT2 was associated with multiple stress responses in both K. pneumoniae and E. coli. Significant changes in the transcription of transition metal ion homeostasis genes were observed in both strains.

2019-06-13 | GSE132637 | GEO